- Motley Fool•yesterday
This drug being sold by J&J "definitely" has $9 billion in peak sales potential, according to Genmab's CEO.
- Market Realist•yesterday
Pfizer was trading at a forward PE multiple of ~13.0x on February 23, 2017, compared to the industry average of ~16.1x.
- Motley Fool•2 days ago
Geron Corp., Cameco Corp., and Kratos Defense & Security Solutions are in sink or swim mode.
JNJ : Summary for Johnson & Johnson - Yahoo Finance
Johnson & Johnson (JNJ)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Bid||122.62 x 200|
|Ask||122.67 x 100|
|Day's Range||120.90 - 122.74|
|52 Week Range||105.04 - 126.07|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||20.70|
|Dividend & Yield||3.20 (2.61%)|
|1y Target Est||N/A|